Amplitude Surgical – Marked Improvement in Operational Performances in H1 2019-20

Regulatory News:

Amplitude Surgical (Paris:AMPLI) (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME plans) (“Amplitude” or the “Group”), French leader on the global surgical technology market for lower-limb orthopedics, today announces its results for the first half of its 2019-20 financial year to the end of December 2019.

Olivier Jallabert, Chairman and CEO of Amplitude Surgical, states: “In the first half of our 2019-20 financial year, the pursuit of our strategy aimed at delivering profitable growth continued to bear fruit. The control of our costs combined with the allocation of resources to our strategic projects enabled us to generate an EBITDA growth of more than 40% to €11.3 million and a Recurring Operating Profit of €0.8 million. Moreover, in the face of the complex situation caused by the COVID-19 pandemic, we firmly believe that the solidity of our financial structure will enable us to cope with the challenges of the coming months.”

In the first half of its 2019-20 financial year, Amplitude Surgical continued to roll-out its strategy and recorded sales of €49.8 million, up 5.8% in actual terms and 5.7% at constant exchange rates, and EBITDA of €11.3 million, an improvement of 41.2%, giving a significant increase in the margin to 22.7%.

Financial summary – actual exchange rates:

€k - IFRS (*)	H1 2019-20	H1 2018-19	Δ
Sales	49,833	47,102	+5.8%
Gross margin	36,277	35,035	+3.5%
as a % of sales	72.8%	74.4%	-160 bps
Sales & Marketing costs	17,582	19,337	-9.1%
General & Administrative costs	5,161	5,648	-8.6%
Research & Development costs	2,223	2,039